Consensus ORIC Pharmaceuticals, Inc. Börse Stuttgart

Equities

4TZ

US68622P1093

Market Closed - Börse Stuttgart Other stock markets 07:03:09 02/07/2024 BST			5-day change	1st Jan Change
7 ^EUR	-1.41%		+6.77%	-12.88%

06-10	Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
05-06	ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on ORIC Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

73bc9594178b3f827849e841fcf.Gj_ycTOIE_fPG8tAu7oizOFWv1Qh7OO5k0MVWjEKF5Q.UnGTBX3iZryNYoI24dNPjrdn-yUYv6_J1nBBDVpyXuZUcYBGf8tRo_ZY-w~603bf97f7f44956de09de9ba910a25d8

Analyst Recommendations on ORIC Pharmaceuticals, Inc.

JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	03-27	MT
HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	03-21	MT
Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	03-12	MT
Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	03-01	MT
Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	02-26	MT
HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	12-13	MT
Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	12-12	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	26/10/23	MT
JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	24/10/23	MT
Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	23/10/23	MT
Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	22/09/23	MT
Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	16/08/23	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	15/08/23	MT
HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	10/05/23	MT
Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	05/04/23	MT
HC Wainwright Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $16	23/03/23	MT
Guggenheim Upgrades ORIC Pharmaceuticals to Buy From Neutral, Price Target is $15	21/03/23	MT
JPMorgan Adjusts Price Target on ORIC Pharmaceuticals to $15 From $16, Maintains Overweight Rating	21/03/23	MT
Oppenheimer Upgrades ORIC Pharmaceuticals to Outperform From Perform, $14 Price Target	16/03/23	MT
Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $9 from $10, Keeps Buy Rating	20/05/22	MT
Citigroup Upgrades ORIC Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $10 From $7	04/04/22	MT
HC Wainwright Downgrades ORIC Pharmaceuticals to Neutral From Buy	25/03/22	MT
Oppenheimer Downgrades ORIC Pharmaceuticals to Perform From Outperform Following Discontinuation of ORIC-101, Removes $52 Price Target	22/03/22	MT
Citigroup Downgrades ORIC Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $7 From $22	22/03/22	MT
Guggenheim Downgrades ORIC Pharmaceuticals to Neutral From Buy	22/03/22	MT